Home / Health / Sling Therapeutics Secures $123M for Eye Disease Drug Trial
Sling Therapeutics Secures $123M for Eye Disease Drug Trial
16 Sep
Summary
- Sling Therapeutics raised $123 million in new funding.
- The funds will advance an experimental oral drug trial.
- The drug targets thyroid eye disease causing vision loss.
Sling Therapeutics announced on September 16, 2026, that it has secured $123 million in funding. This significant capital infusion is earmarked to advance a late-stage clinical trial.
The trial will test an experimental oral drug developed by the company. This treatment aims to address thyroid eye disease, a condition characterized by inflammation and swelling around the eyes.
Thyroid eye disease can result in prominent eye bulging and, in severe cases, lead to vision loss. The successful funding marks a critical step in potentially offering a new therapeutic option for patients.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
